This is a pilot study of the drug bortezomib, given alone for Kaposi's sarcoma (KS). Velcade (also known as bortezomib) has been approved by the Food and Drug Administration (FDA) to treat other types of cancers and relapsed non-Hodgkin's lymphoma. This study is being done to find out if bortezomib is a safe and effective treatment for AIDS-associated KS. There will be about 24 participants in this study nationwide. There will be about 4 participants at UCLA.

Inclusion Criteria:

• HIV positive men and women 18 years of age or older
• Kaposi's sarcoma that has been treated and has either come back or has not gone away
• At least 5 Kaposi's sarcoma lesions on the skin that have not been treated with radiation
• On stable antiretroviral therapy for at least 12 weeks
• Ability to understand informed consent

Exclusion criteria:

• Current active opportunistic infection
• Shingles outbreak within the last 6 months
• Another cancer within the last 5 years
• Pregnancy or breast feeding
• Active hepatitis B or C infection

This study is being conducted by Dr. Ronald Mitsuyasu under IRB #09-12-016-01

If you think you might be interested in participating in this study, please contact Blanca Corea at 310-557-9062 or email at bcorea@mednet.ucla.edu

Return to Clinical Trials main page